FDA Approved PDE4 Inhibitor Roflumilast for Atopic Dermatitis

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions in the U.S.